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Abstract 1	
The hallmarks of cancer was an attempt to describe the underlying principles 2	
of carcinogenesis. In their latest iteration, there is a particular focus on the 3	
role that the microenvironment and signalling between cancer cells and their 4	
neighbors play in the pathology of tumors. Since the original description of the 5	
hallmarks there has been a huge leap forward in our understanding of the 6	
biology of cellular senescence promoting it from an autonomous tumor 7	
suppressor to a complex, dynamic phenotype that can sometimes be tumor 8	
suppressive, but sometimes oncogenic. In particular, our understanding of the 9	
diverse non-autonomous effects that senescent cells can have upon both 10	
cancer cells and the tumor microenvironment suggests that senescent cells 11	
could play a major role in many human cancer types. Here we suggest that 12	
cellular senescence could underpin the biology of many of the hallmarks of 13	
cancer, making it the true power behind the throne.  14	
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1. INTRODUCTION 1	
At the turn of the millennium Hanahan and Weinburg described their 2	
hallmarks of cancer to try and distill the essential underlying changes that 3	
cells undergo to develop into cancer (Hanahan & Weinberg 2000). This was 4	
an attempt to reduce the vast complexity described in various types and 5	
stages of cancer into its six underlying principles. One of these characteristics 6	
was the insensitivity to anti-growth signals or the loss of tumor suppressor 7	
function; their examples centered on the role of the retinoblastoma protein 8	
(RB) and TGF-β as archetypes of autonomous and secreted cytostatic 9	
factors, respectively. In the report, the description of senescence amounted to 10	
a single reference to the recent identification that unrestricted expression of 11	
oncogenic RAS could drive senescence (Serrano et al. 1997). At the time 12	
cellular senescence was seen solely as an autonomous tumor suppressor 13	
mechanism, but little was known of its role throughout the life-cycle and its 14	
complex non-autonomous signalling.  15	
 16	
Over the intervening time period the hallmarks of cancer have been updated 17	
to include two additional hallmarks and two enabling characteristics with 18	
particular focus on the tissue microenvironment. Importantly, over the same 19	
time period there has been a recognition of the ubiquity of senescence in 20	
human diseases and in pre-malignant lesions in particular (Collado & Serrano 21	
2010, Collado et al. 2005). As a tumor suppressor mechanism found in the 22	
earliest stages of cancer, senescence is positioned as a master controller of 23	
premalignant cells and their ultimate fate to be cleared, remain static, or 24	
progress. In addition, senescence has been described in multiple 25	
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physiological contexts such as embryological development (Muñoz-Espín et 1	
al. 2013, Storer et al. 2013), wound healing (Demaria et al. 2014, Jun & Lau 2	
2010) and normal aging (Burd et al. 2013).  3	
 4	
Since the publication of the original hallmarks, it has been the explosion of our 5	
understanding of the ability of senescent cells to co-ordinate other players 6	
within the tumor microenvironment through secreted signals or cell-contact 7	
that suggest that senescence rather than simply being an autonomous tumor 8	
suppressor could underpin many of these hallmarks of cancer. Here we take 9	
advantage of the hallmarks of cancer (highlighted in ‘bold’ in the text) to 10	
discuss the role of senescence in the development and progression of cancer, 11	
in addition to the therapeutic opportunities that senescence presents to treat 12	
both cancer and the side-effects of anti-cancer therapies. 13	
 14	
2. SENESCENCE AS AN AUTONOMOUS TUMOR SUPPRESSOR 15	
2.1. Replicative Senescence 16	
As ‘replicative immortality and sustained proliferative signalling’ are 17	
hallmarks of cancer, the converse, stable proliferative arrest, is the essential 18	
hallmark of senescence. Senescence was first defined in cultured human 19	
diploid fibroblasts (HDFs), as a state of ‘irreversible cell cycle arrest’ caused 20	
by replicative exhaustion: after a certain number of replications, normal HDFs 21	
lose their proliferative capacity, exhibiting morphological (e.g. enlarged cell 22	
body and nuclei) and biochemical (e.g. accumulation of senescence-23	
associated β-galactosidase activity, SAβ-GAL) alterations, called replicative 24	
senescence (HAYFLICK 1965, Salama et al. 2014, Shay & Wright 2000). The 25	
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molecular correlate of ‘replicative exhaustion’ was found to be critically short 1	
telomeres (Harley et al. 1990). Somatic cells in humans lack telomerase 2	
activity, the enzyme responsible for telomeric elongation and each round of 3	
mitosis causes telomeric attrition; critically short telomeres trigger a DNA 4	
damage response (DDR) (Herbig et al. 2004). Thus, the cancer hallmark 5	
‘replicative immortality’ is a state of escape from replicative senescence. 6	
Indeed, it has been shown that short telomeres in mice can limit 7	
tumorigenesis through induction of senescence (Collado et al. 2007, Cosme-8	
Blanco et al. 2007, Feldser & Greider 2007), although it also causes genomic 9	
instability, leading to a modest increase in spontaneous tumor formation in 10	
highly proliferative cell types (Rudolph et al. 1999). Consistently, most 11	
cancers cells aberrantly express telomerase to achieve this state (Kim et al. 12	
1994, Shay & Wright 2011).  13	
 14	
2.2. Oncogene-induced senescence (OIS) 15	
It was also shown that various types of cytotoxic stress could induce a similar 16	
phenotype, collectively termed premature senescence. Principally, 17	
identification of OIS, first in culture (Serrano et al. 1997) and later in vivo 18	
(Braig et al. 2005, Chen et al. 2005, Collado et al. 2005, Lazzerini Denchi et 19	
al. 2005, Michaloglou et al. 2005), substantiated the role for senescence as a 20	
tumor suppressor. 21	
 22	
Initially, ectopic expression of constitutively active H-RAS (Serrano et al. 23	
1997) and downstream effectors, MEK (Lin et al. 1998) or RAF1 (Zhu et al. 24	
1998), were shown to paradoxically induce a senescence-like phenotype in 25	
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culture. Thus, supra-physiological mitogenic signalling somehow triggers anti-1	
proliferative effectors to avoid transformation. However, this process is liable 2	
to bypass in certain situations: when these mitogenic oncogenes are co-3	
expressed with C-MYC or adenoviral E1A, cells fail to undergo senescence 4	
and leads to immortalization with increased sensitivity to apoptosis. (Serrano 5	
et al. 1997, Zhuang et al. 2008). Indeed, loss of c-MYC expression can lead to 6	
a form of senescence (Wu et al. 2007). Considering that senescent cells are 7	
typically resistant to apoptosis, these observations support the idea that 8	
apoptosis and senescence back up each other for tumor suppression (Narita 9	
& Lowe 2005). 10	
 11	
In a series of studies, oncogene- or loss of tumor suppressor-induced 12	
senescence have been identified in various tissues (Braig et al. 2005, Chen et 13	
al. 2005, Collado et al. 2005, Lazzerini Denchi et al. 2005, Michaloglou et al. 14	
2005), as exemplified by melanocytic naevi. The majority of human naevi 15	
(~80%) carry the oncogenic BRAFV600E mutation, as frequently as seen in 16	
malignant melanoma; it is rare that naevi subsequently progress to 17	
melanoma, suggesting that constitutive activation of BRAF is not sufficient for 18	
melanomagenesis (Pollock et al. 2003). Melanocytes from excised human 19	
naevi are largely non-proliferative and show multiple markers of senescence 20	
including expression of p16 and SAβ-GAL (Gray-Schopfer et al. 2006, 21	
Michaloglou et al. 2005).  22	
 23	
2.3. Therapy-induced senescence (TIS) 24	
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In addition to its tumor suppressive role, senescence is also a potential 1	
therapeutic goal in fully developed cancer, termed therapy-induced 2	
senescence (TIS). The first genetic evidence for in vivo TIS precedes that of 3	
the OIS studies: In murine models of lymphoma, when apoptosis is defective, 4	
chemotherapy leads to the accumulation of cells with a p53-dependent 5	
senescent phenotype (Braig et al. 2005, Schmitt et al. 2002). Interestingly, in 6	
the Eµ-myc mouse lymphoma model, tumors in a p53-null background 7	
regress after chemotherapy, whereas Eµ-myc lymphomas with ectopic Bcl2 8	
(apoptosis defective) show no tumor regression. Nevertheless, prognosis of 9	
the latter is much better than the former (Schmitt et al. 2002). Post-treatment 10	
the Eµ-myc-Bcl2 lymphoma cells exhibit a senescent phenotype, suggesting 11	
that a non-apoptotic function of p53 (likely to be senescence) contributes to 12	
the efficacy of the therapy (Schmitt et al. 2002). A TIS-like phenotype was 13	
also identified in human breast cancer isolated from patients after neo-14	
adjuvant therapy (Poele et al. 2002). Following these initial studies, a number 15	
of mouse models have been used to show TIS, some of which are 16	
summarized elsewhere (Pérez-Mancera et al. 2014).  17	
 18	
2.4. The senescence network 19	
It is well recognized that underpinning the senescence response are two 20	
critical tumor suppressor pathways that mediate inhibition of the cell cycle, in 21	
addition to numerous other functions: the p53 (Brugarolas et al. 1995, Serrano 22	
et al. 1997) and p16/RB pathways (See Fig. 1a & sidebar) (Alcorta et al. 1996, 23	
Shay et al. 1991). However, increasing evidence suggest that it might be 24	
more appropriate to view senescence as a combinatorial phenotype of diverse 25	
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effector programs, which can confer sub-phenotypes, forming a high-order 1	
‘pathway network’ (Fig. 1b) (Salama et al. 2014). This is in marked contrast to 2	
apoptosis, which could be seen as a single entity with clearly defined 3	
pathway(s) (Czabotar et al. 2014).  4	
 5	
There is significant cross-talk and co-operativity between p16/RB and p53 6	
pathways: both p16 and the canonical p53 target, p21 are endogenous CDK 7	
inhibitors, which activate RB to repress cell cycle genes, among others. P16 is 8	
in particular has been rather specifically associated with senescence, making 9	
it a robust maker of senescence. In contrast, p53 is involved in wider stress 10	
responsive contexts, including cell cycle, acute DDR and DNA repair, 11	
apoptosis, and metabolism (Levine & Oren 2009). Interestingly, it has recently 12	
been shown that chronic activation of p53, such as seen in senescence, 13	
drives a distinct transcriptional program to that seen in the acute p53 14	
activation, upon DDR (see sidebar) (Kirschner et al. 2015). In addition, p53 15	
has a range of different functions within the senescence context (Johmura & 16	
Nakanishi 2016, Rufini et al. 2013). However, the relationship between p53 17	
and other senescence effectors is not necessary linear: for example, p53 18	
promotes the autonomous aspects of senescence, but as we discuss later, 19	
p53 represses the senescence-associated secretory phenotype (SASP) that 20	
underpins much of the functionality of the senescent cell (Lujambio et al. 21	
2013, Rodier et al. 2009). In addition, it remains to be elucidated how these 22	
two pathways interact within the complex senescence effector network. 23	
 24	
2.5. Stable Exit From Cell Cycle 25	
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Senescence is distinct from quiescence in terms of the ‘irreversible’ nature of 1	
the proliferative arrest. How is the stability of senescence arrest achieved? 2	
This is particularly critical for OIS, which has constitutively ‘sustained 3	
proliferative signalling’. A number of autonomous effectors potentially 4	
contribute to this arrest (Fig. 1b). It has been shown that mutations causing 5	
persistent activation of the RAS pathway provoke a negative feedback 6	
response, which inhibits RAS/PI3K pathway in human cells at various levels in 7	
the pathway (Courtois-Cox et al. 2006). A similar negative feedback was also 8	
observed in the BRAF/MAPK pathway during the BRAF-induced melanocyte 9	
senescence (Wajapeyee et al. 2008). This negative feedback was reported to 10	
be mediated by secreted protein IGFBP7, although its involvement in OIS 11	
might be dependent on cell type or experimental model studied (Scurr et al. 12	
2010, Vizioli et al. 2011, Wajapeyee et al. 2008, 2010). It is also apparent that 13	
other SASP components can reinforce the irreversibility of the senescence 14	
arrest (Acosta et al. 2008, Kortlever et al. 2006, Kuilman et al. 2008).  15	
 16	
Another plausible mechanism is ‘persistent’ DDR (pDDR) accompanied by 17	
chronic activation of the p53 pathway (Fumagalli et al. 2014), as highlighted in 18	
the case of telomere dysfunction. This can be caused, not only by replicative 19	
stress (d'Adda di Fagagna et al. 2003, Herbig et al. 2004) but also by 20	
inhibition of TRF2, a double-stranded telomeric DNA-binding protein essential 21	
for telomere protection (Karlseder et al. 2002, Takai et al. 2003, van Steensel 22	
et al. 1998). Paradoxically, the protective role for TRF2 at chromosomal ends 23	
also appears to contribute to triggering pDDR. It has been suggested that the 24	
activity of TRF2 prevents aberrant chromosomal fusions, partly by serving as 25	
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an endogenous inhibitor of DNA repair (Bae & Baumann 2007). Thus, DNA 1	
damage in telomere regions is essentially irreparable and during senescence 2	
induced by genotoxic stress pDDR foci are preferentially located at the 3	
telomeres (Fumagalli et al. 2012, Hewitt et al. 2012). Interestingly, pDDR foci 4	
have also been identified in non-telomeric regions, collectively called ‘DNA 5	
segments with chromatin alterations reinforcing senescence’ (DNA-SCARS), 6	
which also lack DNA repair proteins (Rodier et al. 2011). These DNA-SCARS 7	
seem to be persistent double strand breaks that remain unrepaired (Galbiati 8	
et al. 2017). Further, the pDDR has also been associated with other forms of 9	
senescence including OIS, which typically exhibits an initial mitotic burst, 10	
causing an S-phase-associated DDR (Bartkova et al. 2006, d'Adda di 11	
Fagagna 2008, Di Micco et al. 2006, Mallette et al. 2007).  12	
 13	
Although pDDR appears to underline many types of senescence, senescence 14	
can be induced without a DDR. For example, ectopic expression of p16 or 15	
p21 is able to drive a senescent phenotype without a DDR (Coppé et al. 16	
2011). More recently, developmental senescence has also been found to be a 17	
critical mediator of embryological development and is not associated with a 18	
DDR (Muñoz-Espín et al. 2013, Storer et al. 2013). 19	
 20	
It has also been suggested that the multiple nuclear and chromatin alterations 21	
seen in senescence might be involved in underpinning the stable cell cycle 22	
arrest (Salama et al. 2014). This was also highlighted in mouse genetic 23	
models of OIS/TIS, where Suv39h1 is essential for senescence: Suv39h1 is a 24	
histone H3 lysine 9 methyl-transferase, which marks heterochromatin (Braig 25	
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et al. 2005, Dörr et al. 2013). Although not described as a cancer hallmark, 1	
epigenetics might be considered to be an ‘enabling characteristic’ for other 2	
hallmarks. Another ‘autonomous’ effector, potentially associated with 3	
senescence arrest is a metabolic switch: Senescence has a distinct metabolic 4	
state compared to cancer, which is accompanied by ‘deregulating cellular 5	
energetics’. We recently reviewed these features of senescence in detail: 6	
epigenetics (Parry & Narita 2016); and metabolism (Pérez-Mancera et al. 7	
2014). Interestingly, increasing evidence suggest interplay between them. For 8	
example, senescence-specific downregulation of the nuclear lamina protein 9	
Lamin B1 has been implicated in gene regulation and senescence-associated 10	
heterochromatic foci (SAHF) formation during OIS (Sadaie et al. 2013). Lamin 11	
B1 has recently been shown to be a substrate of autophagy (Dou et al. 2015), 12	
a nutrient-sensing bulk-protein degradation process, demonstrated to be 13	
activated during senescence (Young et al. 2009). In addition, histone-14	
modifying enzymes are often controlled by metabolic intermediates of 15	
glycolysis and the tricarboxylic acid (TCA) cycle (Lu & Thompson 2012), both 16	
of which appear to be hyper-activated during senescence (Dörr et al. 2013, 17	
Kaplon et al. 2013). Although any causal link between senescence-associated 18	
metabolic changes and histone modifications is unclear, such a link has been 19	
highlighted in cancer by mutations of isocitrate dehydrogenases (IDH), which 20	
normally metabolizes intermediates of the TCA cycle. Mutant IDH converts α-21	
ketoglutarate (α-KG) to 2-hydroxyglutarate (2-HG), which inhibits α-KG-22	
dependent enzyme activities. Such enzymes include the JmjC-domain family 23	
of demethylases and TET proteins; thus, 2-HG inhibits the demethylation of 24	
histones and DNA, respectively (Lu et al. 2012, Turcan et al. 2012). 25	
Hoare and Narita – Ann. Rev. Cancer Biology 
	 12 
Oncogenic mutations in another TCA cycle enyzme fumarate hydratase (FH) 1	
have been shown to induce senescence (Zheng et al. 2015). The mechanism 2	
for induction of this form of senescence appears to be oxidative stress, but it 3	
would be interesting to know how such perturbation of the TCA cycle affects 4	
the epigenetic state and chromatin structure of senescent cells. 5	
 6	
4. NON-AUTONOMOUS ACTIVITIES OF SENESCENCE 7	
Senescence was once viewed as a functional end point of stress response, 8	
but senescent cells are able to express and secrete factors that can exert 9	
profound effects upon surrounding players in the microenvironment, such as 10	
parenchymal, stromal and immune cells, in addition to the extracellular matrix 11	
(Fig. 1c). This secretome consists of a wide variety of cytokines, chemokines, 12	
matrix-modifying enzymes and growth factors that have been linked with 13	
diverse, sometimes contrasting, downstream functional outcomes in different 14	
contexts. The SASP has been linked with outcomes in 6 different domains: (1) 15	
tumor suppression through autocrine reinforcement of senescence; (2) tumor 16	
suppression through paracrine transmission of senescence; (3) tumor 17	
suppression through promotion of immune-mediated surveillance of 18	
senescent cells; (4) oncogenesis through paracrine promotion of 19	
tumorigenesis, through ‘tumor-promoting inflammation’; (5) paracrine 20	
enhancement of ‘stemness’ and plasticity; (6) promotion of angiogenesis.  21	
 22	
4.1. Senescence and Immunity 23	
It has long been recognized that many cancers, such as viral hepatitis-related 24	
hepatocellular carcinoma (HCC) or inflammatory bowel disease-related 25	
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colorectal carcinoma, can develop in the context of chronic tissue 1	
inflammation (Coussens & Werb 2002). Further, inflammation and subsequent 2	
immune cell infiltration portends an improved prognosis in several human 3	
cancers (Pagès et al. 2010, Stanton et al. 2016). Inflammation not only 4	
provides mitogenic stimulation, but also leads to modification of the 5	
extracellular matrix and promotes angiogenesis; therefore, ‘tumor-promoting 6	
inflammation’ is proposed to be an enabling characteristic of other hallmarks 7	
of carcinogenesis, and it is perhaps coupled with the hallmark, ‘avoiding 8	
immune destruction’ (Hanahan & Weinberg 2011). Increased evidence 9	
suggests that senescence, either in tumor or stromal cells, is involved in both 10	
of these processes.  11	
 12	
Within the diverse factors of the SASP, inflammatory cytokines and 13	
chemokines, including IL6, IL8, and IL1, have been used as a representative 14	
subset. These factors are pleiotropic and, not surprisingly, have been reported 15	
to contribute to diverse processes. One feature of activation of the 16	
inflammatory SASP in vivo is immune cell recruitment and subsequent 17	
immune-mediated clearance of senescent cells: senescent cells signal to 18	
different components of the immune system to drive this process (Yevsa et al. 19	
2012). The first evidence for this was shown in a ‘TIS model’ (in a broader 20	
sense), where endogenous p53 is reactivated in fully established cancer (Xue 21	
et al. 2007). In this study, embryonic mouse liver progenitor cells expressing 22	
oncogenic H-RAS and tetracycline-responsive sh-p53 develop cancer when 23	
they are seeded to the livers of mice lacking adaptive immunity; reactivation of 24	
endogenous p53, by switching off the RNAi, results in tumor regression. 25	
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Interestingly, the primary response to the p53 restoration is not cell death but 1	
senescence and a subsequent innate immune response that in turn targets 2	
the senescent tumor cells. This is in contrast to the aforementioned Eµ-myc-3	
Bcl2 lymphoma model, where the primary response to genotoxic 4	
chemotherapy is p53-dependent senescence with no tumor regression 5	
(Schmitt et al. 2002).  6	
 7	
Pre-malignant OIS cells also have significant interactions with the immune 8	
system (Kang et al. 2011). Hydrodynamic tail-vein delivery of NRASG12V-9	
containing transposons in the mouse results in mosaic integration and 10	
induction of hepatocyte OIS, which is accompanied by the SASP-mediated 11	
recruitment of immunocytes and subsequent clearance of senescent cells, 12	
termed senescence surveillance (Kang et al. 2011). In the absence of 13	
functional adaptive, and more specifically CD4+ T-lymphocyte, immunity 14	
persistent RAS-senescent hepatocytes develop into HCC with reduced 15	
expression of p19Arf, a strong senescence effector in mice (Kang et al. 2011), 16	
placing senescence surveillance as an additional tumor suppressive layer. A 17	
more recent study showed that OIS hepatocyte-induced CCL2-CCR2 18	
signaling promotes recruitment of immature myeloid cells (iMC) to the liver 19	
and their differentiation to macrophages, likely to be the major effector cells 20	
downstream of CD4+ T-helper cells, for elimination of OIS hepatocytes 21	
(Eggert et al. 2016).  22	
 23	
This model offers a unique opportunity to study the dynamic mechanisms 24	
underpinning immune destruction and its avoidance, but as mentioned above, 25	
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earlier in vivo OIS studies do not describe immune elimination of senescent 1	
cells (Narita & Lowe 2005). Thus, in both TIS and OIS, the efficiency of 2	
senescence surveillance appears to be model dependent. The reason for the 3	
variation of the long-term fate of senescent cells in vivo, either in TIS or OIS, 4	
is unclear. In the liver OIS model, a CD4+ T-cell-dependent, mutant NRAS-5	
specific reaction critical for senescence surveillance develops in adult mice 6	
after delivery of a genuinely novel tumor antigen. In other genetically modified 7	
mouse models oncogenes (such as K-Ras and BRaf), mostly driven by 8	
endogenous promoters, are expressed during embryonic development and 9	
therefore may be ignored as self-antigens.  10	
 11	
It is also possible that the SASP composition varies with different senescence 12	
drivers. Indeed, in the context of senescence induced by the loss of Pten in 13	
murine prostatic epithelial cells, the SASP is immunosuppressive when 14	
compared to the immunostimulatory SASP of Ras-induced senescence in the 15	
same tissue (Di Mitri et al. 2014, Toso et al. 2014). This Pten-loss SASP 16	
drives the recruitment and function of myeloid-derived suppressor cells, 17	
impairing CD8+ T-lymphocyte-mediated immune surveillance. Utilising 18	
pharmacological inhibition of the JAK/STAT signalling pathway, it is possible 19	
to reprogram the functional output of the SASP in order to repress this SASP-20	
dependent immunosuppressive microenvironment, promoting immune-21	
mediated clearance and improving cancer-related outcomes (Toso et al. 22	
2014). 23	
 24	
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Furthermore, it was recently shown that functionally distinct secretomes are 1	
dynamically regulated during the transition to OIS (Hoare et al. 2016). 2	
NOTCH1, a highly conserved cell surface receptor, previously identified as 3	
both oncogenic and tumor suppressive in different human cancers (Aster et 4	
al. 2017), is transiently activated during the transition to senescence, 5	
temporally associated with a phase of the SASP rich in TGFβ ligands, 6	
collagens and fibronectin. By full senescence, when the SASP includes pro-7	
inflammatory cytokines and fibrolytic matrix-modifying enzymes, NOTCH 8	
activity had returned to baseline. Mechanistically NOTCH achieves this, in 9	
part, through inhibition of C/EBPβ, a key transcription factor controlling the 10	
inflammatory SASP (see sidebar). Importantly, in the liver OIS surveillance 11	
model (Kang et al. 2011), inhibiting Notch signaling in OIS hepatocytes 12	
facilitates their immune clearance, possibly due to a shift towards a more 13	
inflammatory SASP (Hoare et al. 2016), highlighting a therapeutic opportunity 14	
to modulate SASP activity to control tumorigenesis. 15	
 16	
These immunosuppressive aspects of the SASP, represented in the Pten 17	
loss-induced prostate pre-neoplastic tumor (Toso et al. 2014) or NOTCH-type 18	
SASP (Hoare et al. 2016) might explain, at least in part, the varying extent of 19	
senescence surveillance depending on the model. This view might be 20	
extended to the context of advanced cancer, where an immunosuppressive 21	
SASP, derived from either senescent tumor or stromal cells could also be 22	
involved in the cancer hallmark, ‘avoiding immune destruction’ through 23	
diverse mechanisms (Eggert et al. 2016, Ruhland et al. 2016). In recent 24	
years, the recognition that anti-tumoral immunity is actively suppressed 25	
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through inhibitory immune check-points (such as PD-1 and CTLA4) has led to 1	
an explosion in the interest in blocking these mechanisms to release the 2	
endogenous anti-cancer function of the patients own immune system. It would 3	
be interesting to know whether the SASP is also involved in this process. 4	
 5	
In addition to the tumor suppressive consequence of OIS/TIS, it is important 6	
to explore the opposite scenario, where senescent cells are the source of the 7	
cancer hallmark, ‘tumor promoting inflammation’. The same SASP factors 8	
have been shown to promote tumorigenesis or tumorigenic inflammation, 9	
particularly for cells that have escaped senescence arrest in some contexts 10	
(Jackson et al. 2012, Pribluda et al. 2013). In the liver OIS model mentioned 11	
above (Kang et al. 2011), the same tumor suppressive environment that 12	
eliminates OIS hepatocytes can also promote the growth of established HCC 13	
cells. This is mediated through a combination of the SASP (CCL2) and HCC-14	
derived secretory factors: the former recruits iMC to the liver and the latter 15	
inhibits subsequent differentiation of the immunosuppressive iMC into tumor 16	
suppressive macrophages (Eggert et al. 2016), highlighting a complex 17	
interaction between simultaneous secretomes derived from senescent and 18	
tumor cells. This study also reinforces the varying impacts of the same SASP 19	
on tumorigenesis depending on the cell receiving the signal.  20	
 21	
4.2. Senescence and Stroma 22	
In addition to senescence of parenchymal cells critically altering the 23	
microenvironment, there is increasing evidence that senescence of stromal 24	
cells within the tumor-microenvironment can modulate the fate of neighboring 25	
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cancer cells and cancer-related outcomes. In several culture and xenograft 1	
models, senescent fibroblasts have been demonstrated to promote the 2	
proliferation and invasiveness of neighboring epithelial tumor cell lines 3	
through the SASP and stimulation of the epithelial-mesenchymal transition 4	
(Bavik et al. 2006, Coppé et al. 2008, Krtolica et al. 2001, Parrinello et al. 5	
2005), suggesting tumorigenic effects of the SASP on epithelial cells that are 6	
already primed for transformation. In addition, senescence-reporter mice have 7	
highlighted stromal senescence in some tumor models (Burd et al. 2013, 8	
Yoshimoto et al. 2013). 9	
 10	
4.2.1. Stromal SASP and tumorigenesis. The similar effects of stromal 11	
senescence on established cancer have been shown in vivo. For example, 12	
murine melanoma cell lines become more invasive and metastasized more 13	
frequently when implanted into the skin of aged mice, with increased numbers 14	
of senescent dermal fibroblasts (Kaur et al. 2016). Wnt signaling has been 15	
implicated in melanoma ‘phenotype switching’ (i.e. switch between 16	
proliferative and invasive states) (Webster et al. 2015), and this study showed 17	
that sFRP2, a Wnt antagonist, secreted from these fibroblasts is critical for 18	
melanoma invasion and metastasis in this model (Kaur et al. 2016). Stromal 19	
senescence has also been shown to facilitate murine breast cancer 20	
recurrence and metastasis after chemotherapy or surgical removal (Demaria 21	
et al. 2017), suggesting that the stromal SASP contributes to the cancer 22	
hallmark, ‘activating invasion and metastasis’. In these studies, the 23	
interaction between stromal senescence and immunophenotypes was not 24	
addressed. However, stromal SASP was reported to promote tumorigenesis 25	
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through immune modulation in a different model: stromal-specific induction of 1	
senescence or skin-injection of senescent fibroblasts is sufficient to establish 2	
a immunosuppressive microenvironment characterized by increasing myeloid-3	
derived suppressor cells that are capable of inhibiting CD8+ T-cell function 4	
(Ruhland et al. 2016). This environment appears to promote growth of 5	
injected murine tumor cell lines, supporting the potential role for senescence 6	
in the ‘avoiding immune destruction’ hallmark. Stromal senescence in 7	
tumor-microenvironments was highlighted in a senescence-reporter mouse 8	
model, and curiously, those senescent cells include bone-marrow derived 9	
cells: the significance of a senescence-like state in these cells remains to be 10	
elucidated (Burd et al. 2013).  11	
 12	
While the stromal SASP is mostly tumorigenic, its impact on tumor ‘initiation’ 13	
appears context-dependent. Senescence has been shown to play a key role 14	
in tissue homeostasis and damage repair through the SASP (Demaria et al. 15	
2014, Jun & Lau 2010, Krizhanovsky et al. 2008) and the same process could 16	
also affect tumorigenesis. For example, in a mouse model of liver fibrosis 17	
induced by the liver-damaging reagent, CCL4, quiescent hepatic stellate cells 18	
(HSCs) differentiate into proliferative and fibrogenic myofibroblasts (activated 19	
HSCs), which subsequently develop senescence with an inflammatory and 20	
fibrolytic SASP. Thus, the SASP limits fibrosis and, and simultaneously, 21	
recruits immune cells to eliminate the senescent HSCs (Krizhanovsky et al. 22	
2008). In this context, chemically induced HCC development is limited through 23	
tumor suppressive M1 macrophages. However, when HSCs escape 24	
senescence, due to loss of p53, they secrete factors promoting polarization of 25	
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macrophages into a tumorigenic M2 state (Lujambio et al. 2013). HSCs can 1	
also be induced to senescence in the context of genetic and dietary obesity, 2	
where the gut microbiota is altered (Yoshimoto et al. 2013). These bacteria 3	
induced increased concentrations of the toxic bile acid deoxy-cholic acid 4	
(DCA), absorbed through the enterohepatic circulation and provoking the 5	
SASP in HSCs. In contrast to the CCL4-liver damage model, the SASP in this 6	
case promotes chemically-induced HCC.  7	
 8	
The opposing effects of the HSC-SASP on HCC development in these two 9	
models might be, in part, due to the different metabolic state. The extent of 10	
liver damage and fibrosis, the latter appearing absent in the obesity model, 11	
might also need to be considered. These factors might affect the nature of the 12	
immune microenvironment, particularly at the initial stage of tumorigenesis, 13	
potentially an important determinant for the difference in long-term 14	
tumorigenic effects of SASP. Interestingly, the shift from fibrogenic to fibrolytic 15	
secretome in HSCs during senescence development in the CCL4 model is 16	
reminiscent of the NOTCH-regulated SASP switch described above (Hoare et 17	
al. 2016) and NOTCH-mediated stromal senescence was noted in a skin 18	
cancer model (Procopio et al. 2015). Detailed analysis of the dynamic and 19	
context-dependent stromal SASP-immune axis might help to reconcile this 20	
question. 21	
 22	
4.2.3. Senescence and cellular re-programing. One potential mechanism 23	
for the non-autonomous tumor-promoting activity of senescence is the 24	
recently recognized role that senescence and the SASP plays in controlling 25	
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differentiation and the ability to re-program into different cellular fates (Chiche 1	
et al. 2017, Mosteiro et al. 2016, Ocampo et al. 2016, Ritschka et al. 2017). 2	
 3	
Somatic cells can be re-programed into induced pluripotent stem cells in 4	
response to expression of the four Yamanaka factors: Oct3/4; Sox2; Klf4; c-5	
Myc (OSKM). It was previously shown that senescence is a barrier to re-6	
programing in culture (reviewed in (Salama et al. 2014)). Paradoxically, a 7	
recent series of studies indicate that OSKM-mediated reprograming does 8	
occur or even is facilitated in the context of aging or senescence in vivo 9	
(Chiche et al. 2017, Mosteiro et al. 2016, Ocampo et al. 2016, Ritschka et al. 10	
2017). Mosteiro et al. show that the OSKM induction in vivo is associated, not 11	
only with reprograming, but also extensive tissue damage and the 12	
development of senescent cells within the same microenvironment, where 13	
reprograming tends to occur in close proximity to more abundant senescent 14	
cells (Chiche et al. 2017, Mosteiro et al. 2016). Loss of the p16INK4A/p19ARF 15	
locus, which abrogates the senescence barrier, thus enhancing reprograming 16	
in vitro, suppresses in vivo reprograming (Mosteiro et al. 2016). These 17	
observations suggest that reprograming of ‘some cells’ is promoted indirectly 18	
by neighboring senescent cells in vivo. Indeed, selective killing of senescent 19	
cells also suppresses in vivo reprograming (Chiche et al. 2017, Mosteiro et al. 20	
2016). Consistently, the researchers identified that the SASP (IL6 in 21	
particular) facilitates in vivo reprograming. Thus, senescence is both an 22	
autonomous barrier and non-autonomous promoter of reprograming (Chiche 23	
et al. 2017, Mosteiro et al. 2016).  24	
 25	
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Then which cells are preferentially reprogramed? Using the same inducible 1	
OSKM mice, Chiche et al. show that, in skeletal muscle, reprograming occurs 2	
during muscle regeneration after damage, which triggers senescence. 3	
Reprograming mostly occurs in satellite cells, suggesting that progenitor/stem 4	
cells are the preferential origin for reprograming at least in skeletal muscle 5	
(Chiche et al. 2017).  6	
 7	
While these studies used ‘reprogramable mice’, a similar observation was 8	
made in OIS models. Ritschka et al. showed that transient exposure to 9	
senescent-conditioned media induces a stem cell-like gene signature within 10	
differentiated keratinocytes (Ritschka et al. 2017). Thus, senescence induced 11	
after tissue damage is crucial for co-ordinating the response of immune cells 12	
to limit damage, but also for promoting regeneration through induction of 13	
stemness and tissue proliferation, a feature that might be utilized by cancer in 14	
some contexts.  15	
 16	
4.2.2. Senescence and the vasculature. ‘Angiogenesis’ is a critical 17	
hallmark of most cancers, where increased vascularization provides the 18	
increased oxygen and nutrient delivery to permit tumor development and 19	
progression. Senescence has been demonstrated to modulate angiogenesis 20	
in both benign degenerative and malignant diseases through the SASP. 21	
Elimination of senescent cells from the murine skin wound healing model 22	
leads to a reduction in angiogenesis within the healing wound (Demaria et al. 23	
2014). Senescent fibroblasts produce VEGF, a potent trophic factor for 24	
vascular growth and angiogenesis (Coppé et al. 2006); when co-injected with 25	
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tumor cells, senescent fibroblasts promote increased tumor vascularization 1	
compared to non-senescent fibroblasts (Coppé et al. 2006). Senescence-2	
induced angiogenesis has been demonstrated in other models. Retinal 3	
ischaemia, frequently induced by diabetes mellitus and a major cause of sight 4	
loss, is associated with the development of both retinal cell senescence and 5	
secretion of VEGF, in a mouse model (Oubaha et al. 2016). Therapeutically, 6	
antibody-mediated depletion of VEGF reduced progression of the retinopathy 7	
in this model. In the field of cancer, multiple myeloma is able to induce stromal 8	
cell senescence and subsequent secretion of FGF2 which underpins 9	
increased growth and angiogenesis of xenografted myeloma tumors 10	
(Kanehira et al. 2016). Senescent dermal fibroblasts, through secretion of 11	
sFRP2, are also able to provoke increased vascularization of implanted 12	
melanoma tumors (Kaur et al. 2016).  13	
  14	
5. SENESCENCE AS THERAPEUTIC TARGET IN CANCER 15	
As discussed earlier, TIS represents the therapeutic induction of senescence 16	
in fully transformed cells. TIS typically implies genotoxic chemotherapy-17	
induced senescence, but this has been extended. For example, p16 acts to 18	
inhibit CDK4/6, which are activated or amplified in several human cancer 19	
types and therefore the development of specific inhibitors, such as palbociclib, 20	
hold promise as negative regulators of cellular proliferation and therapeutic 21	
inducers of senescence (O'Leary et al. 2016). In the context of breast cancer 22	
the addition of palbociclib to conventional treatment led to a doubling of 23	
progression-free survival (Finn et al. 2015, Turner et al. 2015). In melanoma, 24	
palbociclib is able to induce cellular senescence, even in the context of 25	
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tumors that are resistant to the BRAFV600E inhibitor vemurafenib (Yoshida et 1	
al. 2016).  2	
 3	
However, TIS often involves complex non-autonomous activities, of which net 4	
impact on the cancer microenvironment is difficult to predict. One approach 5	
could be to exploit the autonomous arrest of senescence with minimal SASP 6	
induction. In addition to TIS, effectors of senescence surveillance could be a 7	
potential target to enhance this process, as exemplified by NOTCH inhibition 8	
in OIS hepatocytes (discussed above) (Hoare et al. 2016). But, here we focus 9	
on an alternative avenue that has gained increasing attention: targeted killing 10	
of senescent cells (or ‘senolytics’) of either tumoral or stromal origin. The 11	
pioneering work in this area was made in aging contexts: elimination of 12	
senescent cells in genetically-modified mice, which harbor INK-ATTAC, the 13	
‘killing cassette’ for inducible apoptosis in p16-expressing senescent cells, 14	
extends healthy life span in both premature and naturally aging mice (Baker et 15	
al. 2011, 2016).  16	
 17	
Following this initial genetic approach, several small molecules have been 18	
identified that ‘selectively’ kill senescent cells (Baar et al. 2017, Chang et al. 19	
2016, Yosef et al. 2016, Zhu et al. 2015). Senescent cells are known to be 20	
relatively resistant to apoptosis and transcriptional analyses have revealed 21	
upregulation of several anti-apoptotic factors in some (Yosef et al. 2016, Zhu 22	
et al. 2015), but not all contexts (Baar et al. 2017). Targeting these anti-23	
apoptotic survival pathways with dasatinib and quercertin (Zhu et al. 2015) or 24	
ABT-263/ABT-737 (pan-Bcl inhibitors) (Chang et al. 2016, Yosef et al. 2016) 25	
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leads to reduced viability of senescent, but not proliferating cells. Similar to 1	
the INK-ATTAC model, treatment of aged or irradiated mice with these 2	
compounds results in fewer senescent cells, as well as some improvements in 3	
organ functions.  4	
 5	
More recently, a novel senolytic agent has been developed: a modified 6	
FOXO4 peptide, FOXO4-D-Retro-Inverso (DRI), which interferes with 7	
FOXO4-p53 binding (Baar et al. 2017). Treatment with FOXO4-DRI releases 8	
active p53, which is excluded from the nucleus, triggering apoptosis in 9	
senescent cells, presumably through recruitment of active p53 to 10	
mitochondria. Additionally, treatment with FOXO4-DRI in vivo reduces the 11	
burden of senescent cells and restores physical fitness, hair density and renal 12	
function in both premature and natural aged mice.  13	
 14	
Such ‘rejuvenation’ effects of senolytics in mice are highly promising. In the 15	
natural aging context, clearance of senescent cells in the INK-ATTAC mouse 16	
does not reduce the overall lifetime incidence of cancer, but it significantly 17	
increases both cancer- and non-cancer-related survival (Baker et al. 2016). 18	
However, the efficacy of selectively killing senescent tumor cells (e.g. tumor 19	
TIS plus senolytics) remains to be tested. Nevertheless, mice without cancer, 20	
treated with doxorubicin, a standard anti-cancer agent, developed systemic 21	
senescence and impaired physical function, that could be rescued by 22	
elimination of the senescent cells either by FOXO4-DRI or in a second genetic 23	
mouse model, p16-3MR, containing a thymidine kinase, which kills p16-24	
expressing cells in the presence of ganciclovir (GCV). Thus, senescence 25	
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elimination can neutralize the side-effects of chemotherapy (Demaria et al. 1	
2017). Furthermore, when the p16-3MR mice, implanted with a murine breast 2	
cancer cell line (with no p16-3MR) are treated with the chemotherapy with or 3	
without GCV, mice with GCV show better survival with a lower frequency of 4	
metastasis (Demaria et al. 2017). Thus, clearance of senescent cells either for 5	
preventing the development of cancer or reducing the toxicity of 6	
chemotherapy regimes is also a potential therapeutic target. 7	
SUMMARY POINTS: 8	
1. The hallmarks of cancer describe the mechanisms underlying the 9	
transformation of cells from normal to cancer. Senescence may underpin a 10	
number of these hallmarks. 11	
2. Senescence is an autonomous tumor suppressor, leading to long-term cell 12	
cycle arrest. Senescence can develop after oncogene activation, loss of tumor 13	
suppressors or anti-cancer therapies. 14	
3. Through the senescence-associated secretory phenotype (SASP), 15	
senescent cells have myriad effects upon the microenvironment that can be 16	
pro- or anti-tumorigenic. 17	
4. Through the SASP, senescent cells trigger their own immune-mediated 18	
destruction; if this process is interrupted, persistent senescent cells are 19	
tumorigenic. 20	
5. Senescence is a potential therapeutic target, through modulation of the 21	
composition of the SASP or targeted killing of senescent cells to prevent 22	
cancer or the side effects of anti-cancer therapies. 23	
 24	
FUTURE ISSUES: 25	
Some of the most pressing research needs in the field of senescence and 26	
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cancer are:  1	
1. The development of ‘pure’ autonomous senescence inducers;  2	
2. Understanding the context-dependent nature of the SASP in different 3	
stages of cancer development; what are the mechanisms of antagonist 4	
secretomes in the same microenvironment? 5	
3. The development of diverse methods for ‘mechanism-guided’ senescence 6	
elimination; 7	




The author is not aware of any affiliations, memberships, funding, or financial 12	
holdings that might be perceived as affecting the objectivity of this review. 13	
 14	
ACKNOWLEDGMENTS 15	
We thank members of the Narita lab for comments on this review. MH is 16	
supported by a CRUK Clinician Scientist Fellowship (C52489/A19924). MN is 17	
supported by a Cancer Research UK Cambridge Centre Core Grant 18	
(C14303/A17197).   19	
Hoare and Narita – Ann. Rev. Cancer Biology 
	 28 
REFERENCES 1	
Acosta JC, Banito A, Wuestefeld T, Georgilis A, Janich P, et al. 2013. A 2	
complex secretory program orchestrated by the inflammasome controls 3	
paracrine senescence. Nature Cell Biology. 15(8):978–90 4	
Acosta JC, O'Loghlen A, Banito A, Guijarro MV, Augert A, et al. 2008. 5	
Chemokine signaling via the CXCR2 receptor reinforces senescence. 6	
Cell. 133(6):1006–18 7	
Aird KM, Iwasaki O, Kossenkov AV, Tanizawa H, Fatkhutdinov N, et al. 2016. 8	
HMGB2 orchestrates the chromatin landscape of senescence-associated 9	
secretory phenotype gene loci. The Journal of Cell Biology. 215(3):325–34 10	
Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D, Barrett JC. 1996. 11	
Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in 12	
replicative senescence of normal human fibroblasts. Proc. Natl. Acad. Sci. 13	
U.S.A. 93(24):13742–47 14	
Aster JC, Pear WS, Blacklow SC. 2017. The Varied Roles of Notch in Cancer. 15	
Annu Rev Pathol. 12(1):245–75 16	
Baar MP, Brandt RMC, Putavet DA, Klein JDD, Derks KWJ, et al. 2017. 17	
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in 18	
Response to Chemotoxicity and Aging. Cell. 169(1):132–147.e16 19	
Bae NS, Baumann P. 2007. A RAP1/TRF2 complex inhibits nonhomologous 20	
end-joining at human telomeric DNA ends. Molecular Cell. 26(3):323–34 21	
Baker DJ, Childs BG, Durik M, Wijers ME, Sieben CJ, et al. 2016. Naturally 22	
occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature. 23	
530(7589):184–89 24	
Baker DJ, Wijshake T, Tchkonia T, LeBrasseur NK, Childs BG, et al. 2011. 25	
Clearance of p16Ink4a-positive senescent cells delays ageing-associated 26	
disorders. Nature. 479(7372):232–36 27	
Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, et al. 2006. 28	
Oncogene-induced senescence is part of the tumorigenesis barrier 29	
imposed by DNA damage checkpoints. Nature. 444(7119):633–37 30	
Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S, Nelson PS. 2006. The 31	
gene expression program of prostate fibroblast senescence modulates 32	
neoplastic epithelial cell proliferation through paracrine mechanisms. 33	
Cancer Research. 66(2):794–802 34	
Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, et al. 2011. Distinct p53 35	
Transcriptional Programs Dictate Acute DNA-Damage Responses and 36	
Tumor Suppression. Cell. 145(4):571–83 37	
Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AHFM, et al. 2005. 38	
Oncogene-induced senescence as an initial barrier in lymphoma 39	
development. Nature. 436(7051):660–65 40	
Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ. 41	
1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. 42	
Nature. 377(6549):552–57 43	
Burd CE, Sorrentino JA, Clark KS, Darr DB, Krishnamurthy J, et al. 2013. 44	
Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-45	
luciferase model. Cell. 152(1-2):340–51 46	
Chang J, Wang Y, Shao L, Laberge R-M, Demaria M, et al. 2016. Clearance 47	
of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells 48	
in mice. Nature Medicine. 22(1):78–83 49	
Hoare and Narita – Ann. Rev. Cancer Biology 
	 29 
Chen Z, Trotman LC, Shaffer D, Lin H-K, Dotan ZA, et al. 2005. Crucial role of 1	
p53-dependent cellular senescence in suppression of Pten-deficient 2	
tumorigenesis. Nature. 436(7051):725–30 3	
Chiche A, Le Roux I, Joest von M, Sakai H, Aguín SB, et al. 2017. Injury-4	
Induced Senescence Enables In Vivo Reprogramming in Skeletal Muscle. 5	
Cell Stem Cell. 20(3):407–414.e4 6	
Christophorou MA, Ringshausen I, Finch AJ, Swigart LB, Evan GI. 2006. The 7	
pathological response to DNA damage does not contribute to p53-8	
mediated tumour suppression. Nature. 443(7108):214–17 9	
Collado M, Blasco MA, Serrano M. 2007. Cellular senescence in cancer and 10	
aging. Cell. 130(2):223–33 11	
Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, et al. 2005. Tumour 12	
biology: senescence in premalignant tumours. Nature. 436(7051):642 13	
Collado M, Serrano M. 2010. Senescence in tumours: evidence from mice 14	
and humans. Nat Rev Cancer. 10(1):51–57 15	
Coppé J-P, Kauser K, Campisi J, Beauséjour CM. 2006. Secretion of vascular 16	
endothelial growth factor by primary human fibroblasts at senescence. J. 17	
Biol. Chem. 281(40):29568–74 18	
Coppé J-P, Patil CK, Rodier F, Sun Y, Muñoz DP, et al. 2008. Senescence-19	
associated secretory phenotypes reveal cell-nonautonomous functions of 20	
oncogenic RAS and the p53 tumor suppressor. Plos Biol. 6(12):2853–68 21	
Coppé J-P, Rodier F, Patil CK, Freund A, Desprez P-Y, Campisi J. 2011. 22	
Tumor suppressor and aging biomarker p16(INK4a) induces cellular 23	
senescence without the associated inflammatory secretory phenotype. 24	
Journal of Biological Chemistry. 286(42):36396–403 25	
Cosme-Blanco W, Shen M-F, Lazar AJF, Pathak S, Lozano G, et al. 2007. 26	
Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by 27	
initiating p53-dependent cellular senescence. EMBO Rep. 8(5):497–503 28	
Courtois-Cox S, Genther Williams SM, Reczek EE, Johnson BW, 29	
McGillicuddy LT, et al. 2006. A negative feedback signaling network 30	
underlies oncogene-induced senescence. Cancer Cell. 10(6):459–72 31	
Coussens LM, Werb Z. 2002. Inflammation and cancer. Nature. 32	
420(6917):860–67 33	
Czabotar PE, Lessene G, Strasser A, Adams JM. 2014. Control of apoptosis 34	
by the BCL-2 protein family: implications for physiology and therapy. Nat 35	
Rev Mol Cell Biol. 15(1):49–63 36	
d'Adda di Fagagna F. 2008. Living on a break: cellular senescence as a DNA-37	
damage response. Nat Rev Cancer. 8(7):512–22 38	
d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, et al. 39	
2003. A DNA damage checkpoint response in telomere-initiated 40	
senescence. Nature. 426(6963):194–98 41	
Demaria M, O'Leary MN, Chang J, Shao L, Liu S, et al. 2017. Cellular 42	
Senescence Promotes Adverse Effects of Chemotherapy and Cancer 43	
Relapse. Cancer Discov. 7(2):165–76 44	
Demaria M, Ohtani N, Youssef SA, Rodier F, Toussaint W, et al. 2014. An 45	
essential role for senescent cells in optimal wound healing through 46	
secretion of PDGF-AA. Developmental Cell. 31(6):722–33 47	
Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, et al. 2006. 48	
Oncogene-induced senescence is a DNA damage response triggered by 49	
DNA hyper-replication. Nature. 444(7119):638–42 50	
Hoare and Narita – Ann. Rev. Cancer Biology 
	 30 
Di Mitri D, Toso A, Chen JJ, Sarti M, Pinton S, et al. 2014. Tumour-infiltrating 1	
Gr-1+ myeloid cells antagonize senescence in cancer. Nature. 2	
515(7525):134–37 3	
Dou Z, Xu C, Donahue G, Shimi T, Pan J-A, et al. 2015. Autophagy mediates 4	
degradation of nuclear lamina. Nature. 527(7576):105–9 5	
Dörr JR, Yu Y, Milanovic M, Beuster G, Zasada C, et al. 2013. Synthetic lethal 6	
metabolic targeting of cellular senescence in cancer therapy. Nature. 7	
501(7467):421–25 8	
Eggert T, Wolter K, Ji J, Ma C, Yevsa T, et al. 2016. Distinct Functions of 9	
Senescence-Associated Immune Responses in Liver Tumor Surveillance 10	
and Tumor Progression. Cancer Cell. 30(4):533–47 11	
Feldser DM, Greider CW. 2007. Short telomeres limit tumor progression in 12	
vivo by inducing senescence. Cancer Cell. 11(5):461–69 13	
Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, et al. 2015. The cyclin-14	
dependent kinase 4/6 inhibitor palbociclib in combination with letrozole 15	
versus letrozole alone as first-line treatment of oestrogen receptor-16	
positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): 17	
a randomised phase 2 study. Lancet Oncol. 16(1):25–35 18	
Freund A, Patil CK, Campisi J. 2011. p38MAPK is a novel DNA damage 19	
response-independent regulator of the senescence-associated secretory 20	
phenotype. The EMBO Journal. 30(8):1536–48 21	
Fumagalli M, Rossiello F, Clerici M, Barozzi S, Cittaro D, et al. 2012. 22	
Telomeric DNA damage is irreparable and causes persistent DNA-23	
damage-response activation. Nature Cell Biology. 14(4):355–65 24	
Fumagalli M, Rossiello F, Mondello C, d'Adda di Fagagna F. 2014. Stable 25	
cellular senescence is associated with persistent DDR activation. PLoS 26	
ONE. 9(10):e110969 27	
Galbiati A, Beauséjour C, d'Adda di Fagagna F. 2017. A novel single-cell 28	
method provides direct evidence of persistent DNA damage in senescent 29	
cells and aged mammalian tissues. Aging Cell. 16(2):422–27 30	
Gil J, Peters G. 2006. Regulation of the INK4b-ARF-INK4a tumour suppressor 31	
locus: all for one or one for all. Nat Rev Mol Cell Biol. 7(9):667–77 32	
Gray-Schopfer VC, Cheong SC, Chong H, Chow J, Moss T, et al. 2006. 33	
Cellular senescence in naevi and immortalisation in melanoma: a role for 34	
p16? Br J Cancer. 95(4):496–505 35	
Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell. 100(1):57–70 36	
Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. 37	
Cell. 144(5):646–74 38	
Harley CB, Futcher AB, Greider CW. 1990. Telomeres shorten during ageing 39	
of human fibroblasts. Nature. 345(6274):458–60 40	
HAYFLICK L. 1965. THE LIMITED IN VITRO LIFETIME OF HUMAN DIPLOID 41	
CELL STRAINS. Experimental Cell Research. 37:614–36 42	
Herbig U, Jobling WA, Chen BPC, Chen DJ, Sedivy JM. 2004. Telomere 43	
shortening triggers senescence of human cells through a pathway 44	
involving ATM, p53, and p21(CIP1), but not p16(INK4a). Molecular Cell. 45	
14(4):501–13 46	
Herranz N, Gallage S, Mellone M, Wuestefeld T, Klotz S, et al. 2015. mTOR 47	
regulates MAPKAPK2 translation to control the senescence-associated 48	
secretory phenotype. Nature Cell Biology. 17(9):1205–17 49	
Hewitt G, Jurk D, Marques FDM, Correia-Melo C, Hardy T, et al. 2012. 50	
Hoare and Narita – Ann. Rev. Cancer Biology 
	 31 
Telomeres are favoured targets of a persistent DNA damage response in 1	
ageing and stress-induced senescence. Nat Commun. 3:708 2	
Hoare M, Ito Y, Kang T-W, Weekes MP, Matheson NJ, et al. 2016. NOTCH1 3	
mediates a switch between two distinct secretomes during senescence. 4	
Nature Cell Biology. 18(9):979–92 5	
Jackson JG, Pant V, Li Q, Chang LL, Quintás-Cardama A, et al. 2012. p53-6	
mediated senescence impairs the apoptotic response to chemotherapy 7	
and clinical outcome in breast cancer. Cancer Cell. 21(6):793–806 8	
Johmura Y, Nakanishi M. 2016. Multiple facets of p53 in senescence 9	
induction and maintenance. Cancer Science. 107(11):1550–55 10	
Jun J-I, Lau LF. 2010. The matricellular protein CCN1 induces fibroblast 11	
senescence and restricts fibrosis in cutaneous wound healing. Nature Cell 12	
Biology. 12(7):676–85 13	
Kanehira M, Fujiwara T, Nakajima S, Okitsu Y, Onishi Y, et al. 2016. An 14	
Lysophosphatidic Acid Receptors 1 and 3 Axis Governs Cellular 15	
Senescence of Mesenchymal Stromal Cells and Promotes Growth and 16	
Vascularization of Multiple Myeloma. Stem Cells. 35(3):739–53 17	
Kang C, Xu Q, Martin TD, Li MZ, Demaria M, et al. 2015. The DNA damage 18	
response induces inflammation and senescence by inhibiting autophagy 19	
of GATA4. Science. 349(6255):aaa5612 20	
Kang T-W, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, et al. 2011. 21	
Senescence surveillance of pre-malignant hepatocytes limits liver cancer 22	
development. Nature. 479(7374):547–51 23	
Kaplon J, Zheng L, Meissl K, Chaneton B, Selivanov VA, et al. 2013. A key 24	
role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-25	
induced senescence. Nature. 498(7452):109–12 26	
Karlseder J, Smogorzewska A, de Lange T. 2002. Senescence induced by 27	
altered telomere state, not telomere loss. Science. 295(5564):2446–49 28	
Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, et al. 2016. sFRP2 29	
in the aged microenvironment drives melanoma metastasis and therapy 30	
resistance. Nature. 532(7598):250–54 31	
Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, et al. 1994. 32	
Specific association of human telomerase activity with immortal cells and 33	
cancer. Science. 266(5193):2011–15 34	
Kirschner K, Samarajiwa SA, Cairns JM, Menon S, Pérez-Mancera PA, et al. 35	
2015. Phenotype Specific Analyses Reveal Distinct Regulatory 36	
Mechanism for Chronically Activated p53. PLoS Genet. 11(3):e1005053 37	
Kortlever RM, Higgins PJ, Bernards R. 2006. Plasminogen activator inhibitor-38	
1 is a critical downstream target of p53 in the induction of replicative 39	
senescence. Nature Cell Biology. 8(8):877–84 40	
Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, et al. 2008. 41	
Senescence of activated stellate cells limits liver fibrosis. Cell. 42	
134(4):657–67 43	
Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J. 2001. Senescent 44	
fibroblasts promote epithelial cell growth and tumorigenesis: a link 45	
between cancer and aging. Proc Natl Acad Sci USA. 98(21):12072–77 46	
Kruse J-P, Gu W. 2009. Modes of p53 regulation. Cell. 137(4):609–22 47	
Kuilman T, Michaloglou C, Vredeveld LCW, Douma S, van Doorn R, et al. 48	
2008. Oncogene-induced senescence relayed by an interleukin-49	
dependent inflammatory network. Cell. 133(6):1019–31 50	
Hoare and Narita – Ann. Rev. Cancer Biology 
	 32 
Laberge R-M, Sun Y, Orjalo AV, Patil CK, Freund A, et al. 2015. MTOR 1	
regulates the pro-tumorigenic senescence-associated secretory 2	
phenotype by promoting IL1A translation. Nature Cell Biology. 3	
17(8):1049–61 4	
LaPak KM, Burd CE. 2014. The molecular balancing act of p16(INK4a) in 5	
cancer and aging. Mol. Cancer Res. 12(2):167–83 6	
Lazzerini Denchi E, Attwooll C, Pasini D, Helin K. 2005. Deregulated E2F 7	
activity induces hyperplasia and senescence-like features in the mouse 8	
pituitary gland. Mol. Cell. Biol. 25(7):2660–72 9	
Levine AJ, Oren M. 2009. The first 30 years of p53: growing ever more 10	
complex. Nat Rev Cancer. 9(10):749–58 11	
Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW. 1998. 12	
Premature senescence involving p53 and p16 is activated in response to 13	
constitutive MEK/MAPK mitogenic signaling. Genes & Development. 14	
12(19):3008–19 15	
Lu C, Thompson CB. 2012. Metabolic regulation of epigenetics. Cell Metab. 16	
16(1):9–17 17	
Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, et al. 2012. IDH mutation 18	
impairs histone demethylation and results in a block to cell differentiation. 19	
Nature. 483(7390):474–78 20	
Lujambio A, Akkari L, Simon J, Grace D, Tschaharganeh DF, et al. 2013. 21	
Non-Cell-Autonomous Tumor Suppression by p53. Cell. 153(2):449–60 22	
Mallette FA, Gaumont-Leclerc M-F, Ferbeyre G. 2007. The DNA damage 23	
signaling pathway is a critical mediator of oncogene-induced senescence. 24	
Genes & Development. 21(1):43–48 25	
Michaloglou C, Vredeveld LCW, Soengas MS, Denoyelle C, Kuilman T, et al. 26	
2005. BRAFE600-associated senescence-like cell cycle arrest of human 27	
naevi. Nature. 436(7051):720–24 28	
Mosteiro L, Pantoja C, Alcazar N, Marión RM, Chondronasiou D, et al. 2016. 29	
Tissue damage and senescence provide critical signals for cellular 30	
reprogramming in vivo. Science. 354(6315): 31	
Muñoz-Espín D, Cañamero M, Maraver A, Gómez-López G, Contreras J, et 32	
al. 2013. Programmed cell senescence during mammalian embryonic 33	
development. Cell. 155(5):1104–18 34	
Narita M, Lowe SW. 2005. Senescence comes of age. Nature Medicine, 35	
Sep.,, pp. 920–22 36	
Narita M, Young ARJ, Arakawa S, Samarajiwa SA, Nakashima T, et al. 2011. 37	
Spatial coupling of mTOR and autophagy augments secretory 38	
phenotypes. Science. 332(6032):966–70 39	
O'Leary B, Finn RS, Turner NC. 2016. Treating cancer with selective CDK4/6 40	
inhibitors. Nat Rev Clin Oncol. 13(7):417–30 41	
Ocampo A, Reddy P, Martinez-Redondo P, Platero-Luengo A, Hatanaka F, et 42	
al. 2016. In Vivo Amelioration of Age-Associated Hallmarks by Partial 43	
Reprogramming. Cell. 167(7):1719–1733.e12 44	
Orjalo AV, Bhaumik D, Gengler BK, Scott GK, Campisi J. 2009. Cell surface-45	
bound IL-1alpha is an upstream regulator of the senescence-associated 46	
IL-6/IL-8 cytokine network. Proc. Natl. Acad. Sci. U.S.A. 106(40):17031–47	
36 48	
Oubaha M, Miloudi K, Dejda A, Guber V, Mawambo G, et al. 2016. 49	
Senescence-associated secretory phenotype contributes to pathological 50	
Hoare and Narita – Ann. Rev. Cancer Biology 
	 33 
angiogenesis in retinopathy. Sci Transl Med. 8(362):362ra144–44 1	
Pagès F, Galon J, Dieu-Nosjean M-C, Tartour E, Sautès-Fridman C, Fridman 2	
W-H. 2010. Immune infiltration in human tumors: a prognostic factor that 3	
should not be ignored. Nature Publishing Group. 29(8):1093–1102 4	
Parrinello S, Coppé J-P, Krtolica A, Campisi J. 2005. Stromal-epithelial 5	
interactions in aging and cancer: senescent fibroblasts alter epithelial cell 6	
differentiation. Journal of Cell Science. 118(Pt 3):485–96 7	
Parry AJ, Narita M. 2016. Old cells, new tricks: chromatin structure in 8	
senescence. Mamm. Genome. 27(7-8):320–31 9	
Pérez-Mancera PA, Young ARJ, Narita M. 2014. Inside and out: the activities 10	
of senescence in cancer. Nat Rev Cancer. 14(8):547–58 11	
Poele te RH, Okorokov AL, Jardine L, Cummings J, Joel SP. 2002. DNA 12	
damage is able to induce senescence in tumor cells in vitro and in vivo. 13	
Cancer Research. 62(6):1876–83 14	
Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, et al. 2003. High 15	
frequency of BRAF mutations in nevi. Nature Genetics. 33(1):19–20 16	
Pribluda A, Elyada E, Wiener Z, Hamza H, Goldstein RE, et al. 2013. A 17	
Senescence-Inflammatory Switch from Cancer-Inhibitory to Cancer-18	
Promoting Mechanism. Cancer Cell 19	
Procopio M-G, Laszlo C, Labban Al D, Kim DE, Bordignon P, et al. 2015. 20	
Combined CSL and p53 downregulation promotes cancer-associated 21	
fibroblast activation. Nature Cell Biology. 17(9):1193–1204 22	
Ritschka B, Storer M, Mas A, Heinzmann F, Ortells MC, et al. 2017. The 23	
senescence-associated secretory phenotype induces cellular plasticity 24	
and tissue regeneration. Genes & Development 25	
Rodier F, Coppé J-P, Patil CK, Hoeijmakers WAM, Muñoz DP, et al. 2009. 26	
Persistent DNA damage signalling triggers senescence-associated 27	
inflammatory cytokine secretion. Nature Cell Biology. 11(8):973–79 28	
Rodier F, Muñoz DP, Teachenor R, Chu V, Le O, et al. 2011. DNA-SCARS: 29	
distinct nuclear structures that sustain damage-induced senescence 30	
growth arrest and inflammatory cytokine secretion. Journal of Cell 31	
Science. 124(Pt 1):68–81 32	
Rudolph KL, Chang S, Lee HW, Blasco M, Gottlieb GJ, et al. 1999. Longevity, 33	
stress response, and cancer in aging telomerase-deficient mice. Cell. 34	
96(5):701–12 35	
Rufini A, Tucci P, Celardo I, Melino G. 2013. Senescence and aging: the 36	
critical roles of p53. Nature Publishing Group. 32(43):5129–43 37	
Ruhland MK, Loza AJ, Capietto A-H, Luo X, Knolhoff BL, et al. 2016. Stromal 38	
senescence establishes an immunosuppressive microenvironment that 39	
drives tumorigenesis. Nat Commun. 7:11762 40	
Sadaie M, Salama R, Carroll T, Tomimatsu K, Chandra T, et al. 2013. 41	
Redistribution of the Lamin B1 genomic binding profile affects 42	
rearrangement of heterochromatic domains and SAHF formation during 43	
senescence. Genes & Development. 27(16):1800–1808 44	
Salama R, Sadaie M, Hoare M, Narita M. 2014. Cellular senescence and its 45	
effector programs. Genes & Development. 28(2):99–114 46	
Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, et al. 2002. A 47	
senescence program controlled by p53 and p16INK4a contributes to the 48	
outcome of cancer therapy. Cell. 109(3):335–46 49	
Scurr LL, Pupo GM, Becker TM, Lai K, Schrama D, et al. 2010. IGFBP7 is not 50	
Hoare and Narita – Ann. Rev. Cancer Biology 
	 34 
required for B-RAF-induced melanocyte senescence. Cell. 141(4):717–27 1	
Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. 1997. Oncogenic 2	
ras provokes premature cell senescence associated with accumulation of 3	
p53 and p16INK4a. Cell. 88(5):593–602 4	
Shay JW, Pereira-Smith OM, Wright WE. 1991. A role for both RB and p53 in 5	
the regulation of human cellular senescence. Experimental Cell Research. 6	
196(1):33–39 7	
Shay JW, Wright WE. 2000. Hayflick, His Limit, and Cellular Ageing., Vol. 1 8	
Shay JW, Wright WE. 2011. Role of telomeres and telomerase in cancer. 9	
Semin. Cancer Biol. 21(6):349–53 10	
Stanton SE, Adams S, Disis ML. 2016. Variation in the Incidence and 11	
Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: 12	
A Systematic Review. JAMA Oncol. 2(10):1354–60 13	
Storer M, Mas A, Robert-Moreno A, Pecoraro M, Ortells MC, et al. 2013. 14	
Senescence Is a Developmental Mechanism that Contributes to 15	
Embryonic Growth and Patterning. Cell 16	
Takai H, Smogorzewska A, de Lange T. 2003. DNA damage foci at 17	
dysfunctional telomeres. Current Biology. 13(17):1549–56 18	
Tasdemir N, Banito A, Roe J-S, Alonso-Curbelo D, Camiolo M, et al. 2016. 19	
BRD4 Connects Enhancer Remodeling to Senescence Immune 20	
Surveillance. Cancer Discov. 6(6):612–29 21	
Toso A, Revandkar A, Di Mitri D, Guccini I, Proietti M, et al. 2014. Enhancing 22	
chemotherapy efficacy in pten-deficient prostate tumors by activating the 23	
senescence-associated antitumor immunity. Cell Rep. 9(1):75–89 24	
Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, et al. 2012. IDH1 mutation 25	
is sufficient to establish the glioma hypermethylator phenotype. Nature. 26	
483(7390):479–83 27	
Turner NC, Ro J, André F, Loi S, Verma S, et al. 2015. Palbociclib in 28	
Hormone-Receptor-Positive Advanced Breast Cancer. N. Engl. J. Med. 29	
373(3):209–19 30	
van Steensel B, Smogorzewska A, de Lange T. 1998. TRF2 protects human 31	
telomeres from end-to-end fusions. Cell. 92(3):401–13 32	
Vizioli MG, Possik PA, Tarantino E, Meissl K, Borrello MG, et al. 2011. 33	
Evidence of oncogene-induced senescence in thyroid carcinogenesis. 34	
Endocrine Related Cancer. 18(6):743–57 35	
Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. 2008. Oncogenic 36	
BRAF induces senescence and apoptosis through pathways mediated by 37	
the secreted protein IGFBP7. Cell. 132(3):363–74 38	
Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. 2010. Role for 39	
IGFBP7 in senescence induction by BRAF. Cell. 141(5):746–47 40	
Webster MR, Kugel CH, Weeraratna AT. 2015. The Wnts of change: How 41	
Wnts regulate phenotype switching in melanoma. Biochim. Biophys. Acta. 42	
1856(2):244–51 43	
Wu C-H, van Riggelen J, Yetil A, Fan AC, Bachireddy P, Felsher DW. 2007. 44	
Cellular senescence is an important mechanism of tumor regression upon 45	
c-Myc inactivation. Proc. Natl. Acad. Sci. U.S.A. 104(32):13028–33 46	
Xue W, Zender L, Miething C, Dickins RA, Hernando E, et al. 2007. 47	
Senescence and tumour clearance is triggered by p53 restoration in 48	
murine liver carcinomas. Nature. 445(7128):656–60 49	
Yamakoshi K, Takahashi A, Hirota F, Nakayama R, Ishimaru N, et al. 2009. 50	
Hoare and Narita – Ann. Rev. Cancer Biology 
	 35 
Real-time in vivo imaging of p16Ink4a reveals cross talk with p53. The 1	
Journal of Cell Biology. 186(3):393–407 2	
Yevsa T, Kang T-W, Zender L. 2012. Immune surveillance of pre-cancerous 3	
senescent hepatocytes limits hepatocellular carcinoma development. 4	
Oncoimmunology. 1(3):398–99 5	
Yosef R, Pilpel N, Tokarsky-Amiel R, Biran A, Ovadya Y, et al. 2016. Directed 6	
elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat 7	
Commun. 7:11190 8	
Yoshida A, Lee EK, Diehl JA. 2016. Induction of Therapeutic Senescence in 9	
Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6. 10	
Cancer Research. 76(10):2990–3002 11	
Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, et al. 2013. Obesity-12	
induced gut microbial metabolite promotes liver cancer through 13	
senescence secretome. Nature. 499(7456):97–101 14	
Young ARJ, Narita M, Ferreira M, Kirschner K, Sadaie M, et al. 2009. 15	
Autophagy mediates the mitotic senescence transition. Genes & 16	
Development. 23(7):798–803 17	
Zheng L, Cardaci S, Jerby L, MacKenzie ED, Sciacovelli M, et al. 2015. 18	
Fumarate induces redox-dependent senescence by modifying glutathione 19	
metabolism. Nat Commun. 6:6001 20	
Zhu J, Woods D, McMahon M, Bishop JM. 1998. Senescence of human 21	
fibroblasts induced by oncogenic Raf. Genes & Development. 22	
12(19):2997–3007 23	
Zhu Y, Tchkonia T, Pirtskhalava T, Gower AC, Ding H, et al. 2015. The 24	
Achilles' heel of senescent cells: from transcriptome to senolytic drugs. 25	
Aging Cell. 14(4):644–58 26	
Zhuang D, Mannava S, Grachtchouk V, Tang W-H, Patil S, et al. 2008. C-27	
MYC overexpression is required for continuous suppression of oncogene-28	
induced senescence in melanoma cells. Nature Publishing Group. 29	
27(52):6623–34 30	 	31	 	32	 	33	 	34	
  35	
Hoare and Narita – Ann. Rev. Cancer Biology 
	 36 
Sidebars: 1	
CHRONIC P53 DATABASE 2	
P53 is constantly produced and degraded through the MDM2-mediated 3	
proteasomal system (Kruse & Gu 2009). MDM2 is a canonical transcriptional 4	
target of p53, forming a strong negative feedback loop. Thus, p53 is rapidly 5	
but transiently stabilized upon DNA damage (herein we call this ‘acute p53’). 6	
However, it was recently shown that comparable levels of p53 accumulate on 7	
chromatin in senescent cells in culture (‘chronic p53’). Importantly, it has been 8	
suggested from in vivo genetic models that it is the persistent activation of 9	
p53, rather than the acute p53 response that is more important for the tumor 10	
suppressive activity of p53 (Brady et al. 2011, Christophorou et al. 2006). Yet 11	
genome-wide mapping of p53 binding sites had been conducted almost 12	
exclusively in acute p53 conditions. However, chronic p53-specifc targets 13	
were recently evaluated through integrating p53 ChIP-seq and transcriptomic 14	
datasets, revealing more abundant and distinct p53 targets in the context of 15	
OIS compared to acute DDR (Kirschner et al. 2015). Examples of knowledge-16	
based pathway models of chromatin p53 can be found at http://australian-17	
systemsbiology.org/tp53 (Kirschner et al. 2015). This resource may represent 18	
many tumor-associated p53-targets, which have previously been poorly 19	
recognized. 20	
 21	
P16 REGULATION IN SENESCENCE 22	
p16 is an inhibitor of cyclin dependent kinase (CDK4/6)-dependent 23	
phosphorylation of RB, thus blocking G1/S cell cycle transition, and the p16-24	
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CDK-RB axis is often inactivated in cancer (Gil & Peters 2006). Senescence 1	
is typically defined by combination of multiple senescence features in addition 2	
to long-term cell cycle exit. This is because of the lack of single definitive 3	
markers for senescence (Salama et al. 2014). However, p16 upregulation is 4	
probably one of the most specific features of senescence. p16/RB is also 5	
functionally important for senescence: for example, ectopic expression of p16 6	
is sufficient to induce senescence and loss of p16/RB leads to bypass of 7	
senescence. Thus, p16 is a very useful senescence reporter both in culture 8	
and tissues. p16 transcription is, at least in part, regulated by ETS 9	
transcription factors (TFs), but the entire regulatory TF network remains 10	
unclear. p16 expression is also under complex regulation, involving polycomb, 11	
non-coding RNAs, and high-order chromatin structure (LaPak & Burd 2014). 12	
Nevertheless, the p16 promoter or its relatively small parts have been 13	
successfully used to not only faithfully report p16 expression and senescence 14	
induction, but also induce cell death specifically in p16-expressing senescent 15	
cells in vivo (Baker et al. 2011, Burd et al. 2013, Demaria et al. 2017, 16	
Yamakoshi et al. 2009). 17	
 18	
SASP REGULATION  19	
SASP regulation is best-studied for its inflammatory components. Critical to 20	
SASP expression is a pDDR, dependent on ATM and CHK2, but not on p53 21	
(Coppé et al. 2008, Rodier et al. 2009). Indeed, p53 plays an inhibitory role in 22	
the SASP (Rodier et al. 2009). Transcriptionally, two transcription factors 23	
(TFs), RelA and C/EBPβ, cooperatively induce ‘proximal’ inflammatory SASP 24	
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components, such as IL1 and IL6, which in turn activate these TFs, forming 1	
an amplifying loop (Acosta et al. 2008). Thus, blocking these cytokines 2	
collapses the SASP network (Acosta et al. 2013, Kuilman et al. 2008, Orjalo 3	
et al. 2009). SASP factors, including these cytokines are also under 4	
epigenetic regulation, where the chromatin ‘reader’ BRD4 (Tasdemir et al. 5	
2016) and chromatin architectural protein HMGB2 positively regulate the 6	
SASP (Aird et al. 2016). Several other factors, including post-transcriptional 7	
mechanisms, are involved in the cytokine-TFs loop: p38MAPK activation 8	
induces the SASP by activating NFkB in a DDR-independent manner (Freund 9	
et al. 2011); DDR can activate NFkB by inhibiting ‘selective’ autophagy-10	
degradation of GATA4, which positively regulates IL1a and TRAF3IP2, both 11	
NFkB activators (Kang et al. 2015); NOTCH1 inhibits the inflammatory SASP 12	
through blocking the C/EBPβ activity (Hoare et al. 2016); and mTOR 13	
facilitates IL1a translation (Laberge et al. 2015). mTOR also promotes the 14	
SASP through stabilization of SASP transcripts (Herranz et al. 2015) or 15	
through forming mTOR-(‘global’) autophagy spatial coupling compartment 16	
(TASCC) (Narita et al. 2011, Young et al. 2009), although the relationship 17	
between the TASCC and the other mTOR-mediated mechanisms is unclear.  18	
 19	
FIGURE LEGENDS  20	
Figure 1. Features of cellular senescence. a) The classical view of the 21	
senescence pathway. Premature senescence develops as a consequence of 22	
a diverse range of stressors, such as ionising radiation, unrestricted oncogene 23	
activation or anti-cancer therapies. The cell-cycle arrest of senescence is 24	
underpinned by the p53 / p21 pathway and p16 / RB pathway, which co-25	
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operatively contribute to senescence establishment and maintenance. b-c) A 1	
current view of the senescence network involving both autonomous (b) and 2	
non-autonomous (c) features of senescence. Multiple effector mechanisms 3	
contribute to the autonomous senescence phenotype including the DNA-4	
damage response (DDR) and autocrine reinforcement through the 5	
senescence-associated secretory phenotype (SASP). Oncogene-induced 6	
senescence is often accompanied by senescence-associated heterochromatic 7	
foci (SAHF) and negative feedback loops repressing activity of the RAS / 8	
MAPK / PI3K pathways. c) Senescence is associated with profound non-9	
autonomous effects upon multiple players within the microenvironment. Either 10	
through SASP-paracrine signaling or cell-contact-dependent juxtacrine 11	
signaling, senescent cells are able to promote plasticity, modulate immunity 12	
(typically inflammatory, but can also be immunosuppressive), fibrosis 13	
(typically fibrotic, but can also be fibrolytic), orchestrate tissue repair, drive 14	
angiogenesis and, if persistent, drive chronic inflammation.  Dependent on the 15	
context of the signal-receiving cell, these non-autonomous effects can be 16	
tumour suppressive or pro-oncogenic. Dotted lines represent remote activities 17	
through secretory factors. ‘No arrow head’ lines indicate the effect can be 18	
either promoting or suppressing.  19	
 20	
Figure 2. Senescence and the Hallmarks of Cancer. Recent work has 21	
highlighted the diverse range of autonomous and non-autonomous features of 22	
senescence in various models. Some of these features are tumour 23	
suppressive, consistent with the previous view of senescence as a tumour 24	
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suppressor mechanism, but other features serve to promote development and 1	
progression of cancer. We summarise these features here in this pseudo-2	



































Figure 1. Hoare and Narita, Ann Rev Canc Bio
Figure 1. Features of cellular senescence. a) The classical view of the senescence pathway. 
Premature senescence develops as a consequence of a diverse range of stressors, such as 
ionising radiation, unrestricted oncogene activation or anti-cancer therapies. The cell-cycle 
arrest of senescence is underpinned by the p53 / p21 pathway and p16 / RB pathway, which 
co-operatively contribute to senescence establishment and maintenance. b-c) A current view 
of the senescence network involving both autonomous (b) and non-autonomous (c) features 
of senescence. Multiple effector mechanisms contribute to the autonomous senescence phe-
notype including the DNA-damage response (DDR) and autocrine reinforcement through the 
senescence-associated secretory phenotype (SASP). Oncogene-induced senescence is 
often accompanied by senescence-associated heterochromatic foci (SAHF) and negative 
feedback loops repressing activity of the RAS / MAPK / PI3K pathways. c) Senescence is 
associated with profound non-autonomous effects upon multiple players within the microenvi-
ronment. Either through SASP-paracrine signaling or cell-contact-dependent juxtacrine sign-
aling, senescent cells are able to promote plasticity, modulate immunity (typically inflammato-
ry, but can also be immunosuppressive), fibrosis (typically fibrotic, but can also be fibrolytic), 
orchestrate tissue repair, drive angiogenesis and, if persistent, drive chronic inflammation.  
Dependent on the context of the signal-receiving cell, these non-autonomous effects can be 
tumour suppressive or pro-oncogenic. Dotted lines represent remote activities through secre-
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Figure 2. Senescence and the Hallmarks of Cancer. 
Recent work has highlighted the diverse range of auton
omous and non-autonomous features of senescence in 
various models. Some of these features are tumour 
suppressive, consistent with the previous view of 
senescence as a tumour suppressor mechanism, but 
other features serve to promote development and 
progression of cancer. We summarise these features 
here in this pseudo-heatmap and link them to the hall-
marks of cancer in a simplified manner.
